Idarucizumab for Reversal of Dabigatran: Multicenter Real-World Experience

Paola Alejandra Barzallo Burbano,Mar Meijón, Nuria Revilla Calvo, María Jesús Blanco Bañares,Begoña Fernández, Ramón Rodríguez-González, María Elena Sola Aparicio,Belén Rosado Sierra, Susana Asenjo Correa, Isabel Gutiérrez,María Pilar Llamas Sillero,José L. Díez-Martín,Gloria Pérez-Rus,Cristina Pascual Izquierdo

Blood（2021）

引用 2|浏览6

暂无评分

摘要

Introduction: Idarucizumab is a humanized monoclonal antibody fragment that binds to dabigatran and reverses its anticoagulant activity. It has been available in Spain since June 2016 and is indicated for imminent surgery or invasive procedures and life-threatening bleeding. The aim of the study was to describe the actual experience with idarucizumab in different centers in Madrid.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要